TORC1 inhibition increases Adc17 and the proteasome
To determine how yeast cells maintain proteasome homeostasis, we decided to investigate the pathway regulating Adc17. Adc17 is upreg ulated by diverse stresses that impose a high burden on the proteas ome, indicating that it is a component of an unknown generic stress response. Because Adc17 is induced by tunicamycin, an inducer of the unfolded protein response (UPR) 11 , we deleted the UPR genes IRE1 or HAC1 (ref. 11 ). This prevented tunicamycinmediated induction of the UPR marker Kar2, as expected 11 , but not that of Adc17 (Fig. 1a ), indicating that ADC17 was not a UPR target gene. We tested Adc17 induction by tunicamycin in mutants thought to regulate Adc17 from a genomewide regulation study 12 , and found that deletion of SFP1 abolished Adc17 but not Kar2 induction by tunicamycin ( Fig. 1b) . Adc17 induction by tunicamycin was higher in a strain carrying a hypo morphic allele of MRS6, a negative regulator of Sfp1 (Extended Data Fig. 1a ). Sfp1 is a stress and nutrientsensitive regulator of cell growth with dual function [13] [14] [15] . Under optimal growth conditions, Sfp1 is located in the nucleus and can activate transcription of ribosomal protein genes, but it relocalizes to the cytosol upon stress 13, 14 . Sfp1 is acti vated by TORC1, and in turn negatively regulates TORC1 signalling, as a feedback mechanism 15 . In the absence of Spf1, TORC1 is hyperactive 15 . Thus, SFP1 deletion could prevent Adc17 induction directly or by overactivating TORC1. Adc17 induction by tunicamycin ( Fig. 1a, b ) coincided with Sfp1 relocalization from the nucleus to the cytosol (Extended Data Fig. 1b ), suggesting that Sfp1 may regulate Adc17 not directly, but instead indirectly through TORC1. Tunicamycin inhibits TORC1 signalling 15 , as observed ( Fig. 1c ) with the phosphorylation of the TORC1 effector Sch9 (ref. 16 ). In the absence of Sfp1, TORC1 was hyperactive 15 (Fig. 1c ), and it remained active during tunicamycin mediated stress, while Adc17 induction was abolished ( Fig. 1c ), sug gesting that Sfp1 regulated Adc17 via TORC1. Confirming this, rapa mycin, a selective inhibitor of TORC1 (ref. 17) induced Adc17 (Fig. 1d ). Deletion of SFP1 abolished induction of Adc17 by tunicamycin but not by rapamycin ( Fig. 1e ) because SFP1 deletion affected Adc17 expression by hyperactivating TORC1 (Fig. 1f ). To confirm this using a genetic approach, we examined Adc17 regulation in the thermosensitive kog1-1 mutant. Kog1 (Fig. 1f ) is the yeast homologue of Raptor, a subunit of TORC1 (ref. 18 ). Inactivation of KOG1 inhibited TORC1, as expected 18 , and induced Adc17 (Fig. 1g ), indicating that selective TORC1 inhi bition induces Adc17. We investigated whether rapamycin increased proteasome abundance. Consistent with our previous results for tuni camycin 10 , proteasome levels increased by more than twofold after 3 h of rapamycin treatment ( Fig. 1h , i). Thus, inhibition of the central stress and growth controller, TORC1, increases abundance of Adc17 and of the proteasome in yeast. nonUPR mutants sensitive to tunicamycin. The mitogenactivated pro tein kinases (MAPKs) Hog1 and Mpk1 were important for tunicamycin stress survival in yeast ( Fig. 2a ), as expected 20 , unlike the other MAPKs Fus3, Kss1 and Smk1 ( Fig. 2a ); Hog1 being advantageous and Mpk1 essential for stress survival (Fig. 2b ). Adc17 induction by tunicamycin was compromised in HOG1 deleted cells and abolished in cells lack ing a functional allele of MPK1 ( Fig. 2c and Extended Data Fig. 2a , b) revealing a perfect correlation between tunicamycin stressresistance and Adc17 induction. Genetic interaction studies showed that overex pression of HOG1 failed to restore tunicamycin resistance and Adc17 induction in mpk1Δ cells ( Fig. 2d, e ), while overexpression of MPK1 increased both tunicamycin resistance and Adc17 induction in hog1Δ cells ( Fig. 2f, g) . Thus, signalling through Mpk1 is required for Adc17 induction and tunicamycin survival.
We examined if Mpk1 was required for Adc17 induction by rapamycin. MPK1 is negatively regulated by TORC1 and essential for rapamycin survival 21, 22 . Unlike the other MAPK, Mpk1 was essential for both cell viability and Adc17 induction in the presence of rapamycin (Extended Data Fig. 2c-e ). HOG1 contributed to Adc17 upregulation by tunicamycin ( Fig. 2c ) but not by rapamycin (Extended Data Fig. 2d ). HOG1 was dispensable for survival in the presence of rapamycin (Extended Data Fig. 2c ). Thus, induction of Adc17 and rapamycin resistance are perfectly correlated (Extended Data Fig. 2c, d ). In agree ment with a previous study 23 , the levels of Mpk1 increased in response to tunicamycin treatment (Extended Data Fig. 2d ), but this increase was markedly attenuated in hog1Δ cells (Extended Data Fig. 2d ). Thus, one key function of Hog1 is to regulate Mpk1 levels ( Fig. 2h) , providing an explanation for why Mpk1 overexpression in hog1Δ cells rescued tunicamycinresistance and Adc17 induction ( Fig. 2f, g) . Over time, both Mpk1 phosphorylation and abundance were increased by tunicamycin and rapamycin treatment and this preceded Adc17 induction (Extended Data Fig. 3a, b ). Bck1, Mkk1 and Mkk2, three kinases that are upstream of Mpk1 (ref. 24) , were also required for Adc17 induction by tunicamycin and rapamycin treatment (Extended Data Fig. 3c, d) . Congo red, a cellwalldamaging agent and known inducer of the Mpk1 MAPK pathway 24 also induced Adc17, in a Mpk1dependent manner (Extended Data Fig. 3e ). These results indicate that diverse challenges inhibiting TORC1 signal to the Mpk1 MAPK to induce the proteasome assembly chaperone Adc17.
Mpk1 is a master regulator of the proteasome
We focused on Mpk1 because it is essential for Adc17 induction ( Fig. 3a ) and examined whether Mpk1 regulated proteasome abundance. Deleting MPK1 completely abolished the tunicamycin or rapamycin induced increase of 26S proteasomes while increasing the abundance of the free core particles ( Fig. 3b-d ). This defect is symptomatic of regulatory particle assembly defects [6] [7] [8] , and a hallmark of adc17Δ cells in response to stress 10 . However, the mpk1Δ cells ( Fig. 3b-d ) appeared more severely affected than adc17Δ cells 10 , suggesting that other MPK1regulated factors assist regulatory particle assembly. We found that all the known yeast RACs: Nas2, Nas6, Hsm3 and Rpn14 were induced by treatment with tunicamycin, rapamycin or Congo red in wildtype cells ( Fig. 3e and Extended Data Fig. 3f ). Genetic inactivation of TORC1 in kog1-1 cells also induced all RACs at the nonpermissive temperature ( Fig. 3f ). Induction of all yeast RACs by tunicamycin and rapamycin was abolished in mpk1Δ, bck1Δ and mkk1/2Δ cells ( Fig. 3g and Extended Data Fig. 3g , h). Overexpression of different combi nations of three RACs markedly improved tunicamycin resistance in mpk1Δ cells (Extended Data Fig. 4a ). Conversely, the deletion of three RACs severely impaired cell viability in the presence of rapamy cin (Extended Data Fig. 4b ). Thus, regulating the expression of RACs is a key function of Mpk1. These results reveal that downstream of TORC1 inhibition, signalling through the Mpk1 MAPK pathway coor dinates the induction of all RACs to control proteasome abundance and viability upon various stresses.
Tunicamycin and rapamycin increased 26S abundance in wildtype cells and increased free core particles in mpk1Δ cells ( Fig. 3b ), suggesting that core particle assembly might also be regulated. We analysed the levels of the core particle assembly chaperones proteasome biogenesis associated (Pba)1-4 (refs 25, 26) after tunicamycin treatment, the most potent inducer of core particles in mpk1Δ cells ( Fig. 3b, d ). In wildtype cells, tunicamycin treatment increased the level of Pba1 and Pba2 but not the level of Pba3 and Pba4 (Extended Data Fig. 5a-d) . Thus, the increase in core particles was accompanied by an increase of the assembly chaperones Pba1 and Pba2. This increase was unaltered upon MPK1 deletion (Extended Data Fig. 5a-d ). This demonstrates that Pba1 and Pba2 are upregulated by the stress caused by tunicamycin treatment and their regulation is independent of Mpk1. The mechanism of Mpk1 independent regulation of Pba1 and Pba2 will be an important topic for future study.
We examined the regulation of proteasome subunits. Both tunica mycin and rapamycin treatment increased the levels of proteasome subunits, and this increase required Rpn4, the transcription factor controlling expression of proteasome subunits 27 (Extended Data Fig.  6a, b ). Rpn4 increased upon tunicamycin or rapamycin treatment (Extended Data Fig. 6c ). In contrast, Adc17 is upregulated independently of Rpn4 upon diverse stresses (ref. 10) , and all yeast RACs show this same pattern of regulation (Extended Data Fig. 6b ). Upregulation of proteasome subunits depends on Rpn4, and upregulation of all known RACs is independent of Rpn4. Deletion of MPK1 completely abrogated the tunicamycin and rapamycininduced upregulation of proteasome subunits, indicating that Mpk1 is a master regulator of proteasome homeostasis ( Fig. 4a and Extended Data Fig. 6d ). Article reSeArcH
We identified a weak genetic interaction between RPN4 and MPK1, and found that both were required for survival in response to tunicamycin treatment (Extended Data Fig. 6e, f ). Tunicamycin and rapamycin increased Rpn4 levels to wildtype levels in mpk1Δ cells (Extended Data Fig. 6g ), suggesting that Mpk1 is acting downstream of the tran scription factor Rpn4, possibly posttranscriptionally. At the protein level, MPK1 deletion completely abrogated the induction of proteasome subunits and RACs by rapamycin treatment (Fig. 4a) . At the mRNA level, rapamycin only modestly, yet repro ducibly, increased abundance of RACs and proteasome subunits mRNA (Fig. 4b ), and this increase was similar in wildtype and mpk1Δ cells ( Fig. 4b ). Rpn4 induction was similar in both strains (Extended Data Fig. 6g ). Blocking the syn thesis of new proteins with cycloheximide for 4 h did not change the abundance of proteasome subunits and RACs, indicating that they were stable over this time period (Extended Data Fig. 6h, lanes 1  and 4) . Likewise, the stability of proteasome subunits and RACs appeared similar in mpk1Δ cells and wildtype cells (Extended Data Fig. 6i ). However, cycloheximide completely blocked induction of proteasome subunits and RACs by tunicamycin and rapamycin in wild type cells (Extended Data Fig. 6h ). Together these results reveal that the MAPK Mpk1 coordinates the translation of proteasome subunits and RACs to provide the increased proteasome abundance required to sustain cell viability.
Mpk1 adapts proteasome degradation to rising needs
We analysed the consequences of the MPK1dependent increase of proteasome abundance on protein degradation. Polyubiquitinated conjugates represent a hallmark of impaired proteasomal degrada tion and were slightly elevated in mpk1Δ cells compared to wild type (Fig. 5a, b ). This defect was exacerbated upon tunicamycin or rapa mycin treatment (Fig. 5a, b ), suggesting impaired proteasomal deg radation, and providing an explanation for why mpk1Δ cells failed to survive tunicamycin ( Fig. 2a ) or rapamycin treatment (Extended Data Fig. 2c ).
We examined the degradation of diverse proteasome reporter substrates. The metastable Ura33 reporter 28 was rapidly degraded in wildtype cells cultured at 37 °C, but not in cells harbouring a thermo sensitive mutation in the proteasome subunit Rpt4 (Extended Data Fig. 7a, b) . Similarly, the degradation of the reporter substrate was strik ingly compromised in mpk1Δ cells (Extended Data Fig. 7c, d) . The deg radation of the two wellcharacterized proteasome reporter substrates, CPY*-HA and ΔssCPY*-GFP, which are localized in the endoplasmic reticulum and in the cytosol, respectively 29, 30 , was also compromised in mpk1Δ cells ( Fig. 5c-f ). The protein degradation defect of mpk1Δ cells was more pronounced in cells challenged with tunicamycin and rapamycin treatment (Extended Data Fig. 7e-l) . Together with the previous findings, this demonstrates that Mpk1 maintains adequate levels of proteasome required to sustain protein degradation and cell viability under challenging conditions.
Evolutionary conservation of proteasome regulation
Four RACs are evolutionarily conserved with p27, p28, S5b and Rpn14 being human orthologues of the yeast Nas2, Nas6, Hsm3 and Rpn14, respectively [5] [6] [7] [8] [9] . We investigated whether the TORC1 and Mpk1 regu lation of RACs was evolutionarily conserved. Inhibition of mTOR by Torin1 rapidly increased the levels of all mammalian RACs (Fig. 6a, b) , similar to what was found in the experiments in yeast (Fig. 3e, f) . mTOR inhibition resulting from nutrient starvation also increased the RACs (Extended Data Fig. 8a, b) . As in yeast, the concerted increase of the RACs was accompanied by an upregulation of proteasome subunits (Fig. 6a, b) , and resulted in an increase in the levels of 26S proteasome (Fig. 6c, d and Extended Data Fig. 8c, d) . This response was acute, with a rapid return to basal levels ( Fig. 6a-d) . As previously reported 31 , singly capped proteasome RPCP (CP, core particle; RP, regulatory par ticle) was more abundant than doubly capped proteasome RP 2 CP in mammalian cells (Fig. 6c) .
Conversely, medium replenishment to increase nutrient supply and activate mTORC1 had the opposite effect resulting in S6K1 phosphoryl ation (Extended Data Fig. 9a ) and decreasing abundance of both RACs (Extended Data Fig. 9a, b ) and proteasome (Extended Data Fig. 9c, d) . Rapamycin, a selective mTORC1 inhibitor, also acutely and transiently induced the RACs as well as proteasome subunits (Extended Data Fig. 10 ), confirming that, as in yeast, mTORC1 controls proteasome homeostasis. We wondered whether ERK5 (also known as MAPK7) (ref. 32) , the mammalian orthologue of Mpk1, also regulates protea some abundance. ERK5 overexpression in yeast rescued tunicamycin resistance in mpk1Δ cells (Fig. 6e ). Knocking down ERK5 with short interfering RNA (siRNA) in human cells resulted in a decrease of the four mammalian RACs p27, p28, S5b and Rpn14 (Fig. 6f, g) , as well as the 26S proteasome (Fig. 6h, i) . Thus, mammalian ERK5, like yeast Mpk1, controls RACs and thereby acts as a switch to control proteasome abundance.
Discussion
Here we report a general and evolutionarily conserved homeostatic response that increases proteasome abundance as needed, through the coordinated upregulation of regulatory particle assembly chaperones and proteasome subunits. The master regulators of growth and stress, TORC1 and Mpk1/ERK5 are central to this response. Consistent with the general principle of homeostatic responses, we observed that pro teasome increase is an acute and rapidly reversible response. Trying to identify the other components of this proteasome homeostatic response, in particular the mechanisms regulating 20S assembly and determining how proteasome levels return to baseline after an acute increase will be the subject of future studies.
Our results also provide a framework for resolving inconsistences in previous observations. It was reported that when cultured in absence of serum, proteasomal degradation is increased in cells lacking Tsc2, a negative regulator of TORC1 (ref. 33) . In contrast to this, a recent study reported that mTOR inhibition activates proteasomal degradation by a mechanism proposed to be driven by increased ubiquitination 34 .
Considering this in light of our results, it may be the adaptive response to the stress resulting from the lack of Tsc2 combined with serum star vation that increases proteasomal degradation in Tsc2 −/− cells, rather than Tsc2 deletion per se.
In line with our findings is the wellestablished notion that mTOR activation enhances anabolic processes and represses catabolic processes 19, 35 . mTORC1 is known to repress autophagy. We show here that TORC1 restricts proteasome abundance and this is rapidly allevi ated upon TORC1 inhibition. Therefore, the same controller TORC1 restricts the abundance of the two cellular proteolytic systems, the proteasome and autophagy. Our findings integrate the regulation of proteasome assembly and abundance with growth and cellular metab olism, and suggest that the increased proteasome capacity resulting from TORC1 inhibition may also contribute to the benefit of the widely used TORC1 inhibitors.
The current prevailing view is that protein degradation is largely regulated at the level of ubiquitination. Here we demonstrate that mod ulating proteasome abundance is an important component of regula tion of proteasomal degradation. Adapting proteasome abundance is vital to cope with overwhelming cellular needs, implying that protea some abundance can be rate limiting under critical conditions. The evolutionary conservation of the TORC1 and Mpk1/ERK5 pathway controlling proteasome abundance further highlights the importance of this regulation.
The pathway identified here can be used as a unique switch to increase proteasome assembly and abundance on demand. Because many human diseases are associated with accumulation of misfolded proteins, increasing proteasome abundance by manipulating the switches identified here could be used as a generic strategy to reduce the burden of misfolded proteins that accumulate in such agerelated diseases.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. in yeast and βactin in mammalian cells and expressed as fold change. Data were analysed using unpaired Student's ttest or repeated measures analysis of variance (oneway ANOVA or twoway ANOVA where indicated). The level of significance was set at *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; NS, not significant.
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Extended Data Figure 3 | Mpk1 MAPK pathway is essential for stressmediated RACs induction. a, b, Immunoblots of the indicated proteins in lysates of wildtype yeast cells ± tunicamycin (a) or rapamycin (b) for the indicated time. c, g, Immunoblots of the indicated proteins in lysates of wildtype and bck1Δ cells cultured ± tunicamycin or rapamycin for 4 h. d, h, Immunoblots of the indicated proteins in lysates of wildtype and mkk1/2Δ cells cultured ± tunicamycin or rapamycin for 4 h. e, f, Immunoblots of the indicated proteins in lysates of wildtype or mpk1Δ cells ± 50 μg ml −1 Congo red (CR) for 4 h. Representative results of at least three independent experiments (biological replicates) are shown.
